drugset / Trial / NCT00257023

An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia

NCT00257023

Phase 2 Completed 52 enrolled Janssen Pharmaceutical K.K.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, effectiveness, and plasma concentration of paliperidone (an antipsychotic medication) given once daily in the treatment of patients with schizophrenia

Timeline

Start
2005-02
Primary completion
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Paliperidone Unknown 3 mg Oral
Subject Paliperidone Unknown 9 mg Oral
Subject Paliperidone Unknown 15 mg Oral

Indications